EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool

Christopher W J McChalicher, Mary-Jane Lombardo, Sahil Khanna, Gregory J McKenzie, Elizabeth M Halvorsen, Sanabel Almomani, Brian Schuster, Brooke R Hasson, Barbara H McGovern iD, David S Ege, John G Auniņš

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Christopher W J McChalicher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Seres Therapeutics, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Gastrointestinal Microbiome, Microbiota, Clostridium Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seres Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although fecal microbiota transplant has been used to prevent recurrent Clostridioides difficile infection (rCDI), documented pathogen transmissions highlight inherent safety risks of minimally processed stool. We describe manufacturing processes for fecal microbiota spores, live (VOWST; VOS, formerly SER-109), a microbiota-based oral therapeutic of Firmicutes spores.

Methods

Bacterial inactivation kill curves were obtained after ethanol exposure for 4 model organisms spiked into process intermediates.

Results

Bacterial log reduction factors ranged from 6.5 log10 to 7.4 log10 and lysis of spiked organisms occurred rapidly within 30 seconds.

Conclusions

These experiments demonstrate substantial and rapid inactivation of representative organisms, supporting the potential benefit of VOS manufacturing processes to mitigate risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileGastrointestinal MicrobiomeMicrobiotaClostridium InfectionsHumansFecesFecal Microbiota TransplantationRecurrence

Stichwörter der Autor:innen

Clostridioides difficile infectionmicrobiomemicrobiome therapeutic

Autor:innen und Institutionen

  • Seres Therapeutics, Cambridge, Massachusetts, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Barbara H McGovern

Förderung

  • Seres Therapeutics

Zitieren

APA

McChalicher, C. W. J., Lombardo, M. J., Khanna, S., McKenzie, G. J., Halvorsen, E. M., Almomani, S., Schuster, B., Hasson, B. R., McGovern, B. H., Ege, D. S., & Auniņš, J. G. (2023). Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad298

Vancouver

McChalicher CWJ, Lombardo MJ, Khanna S, McKenzie GJ, Halvorsen EM, Almomani S, et al. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad298

BibTeX
@article{McChalicher2023,
  author = {McChalicher, Christopher W J and Lombardo, Mary-Jane and Khanna, Sahil and McKenzie, Gregory J and Halvorsen, Elizabeth M and Almomani, Sanabel and Schuster, Brian and Hasson, Brooke R and McGovern, Barbara H and Ege, David S and Auniņš, John G},
  title = {Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad298}
}
Kostenlos starten →